Tom Jordan Ph.D. is the primary inventor of aldehyde trap therapy (1) and has worked in this field for over two decades.  He was the founding Chairman and CEO of Neuron Systems (2), where he recruited a renowned team of drug developers from Merck and advanced the first generation of aldehyde traps from concept to clinic.  Tom has three graduate degrees from Harvard University in neuroscience, computational chemistry and immunology. 

​

Jack Chabala Ph.D. (deceased) was a renowned medicinal chemist who invented ivermectin at Merck, led medicinal chemistry at Merck and BMS, co-founded Pharmacopeia and co-invented reproxalap at Neuron Systems as a chemistry advisor on its Scientific Advisory Board.

​

Adnan Tufail M.D., Professor of Ophthalmology at the Institute of Ophthalmology at University College London, is an expert in the etiology of retinal diseases and consults internationally to pharmas and biotechs in novel therapeutic strategies, clinical development and emerging diagnostic technologies for retinopathies that lead to blindness.  Adnan was Chief Medical Officer at Neuron and on its Clinical Advisory Board.

​

Mark Blumenkranz M.D. is the HJ Smead Professor Emeritus and former Chairman of the Department of Ophthalmology at Stanford Medical School.  Mark has co-founded multiple biotechs, received the distinguished Lifetime Achievement Award of the American Academy of Ophthalmology, and was a member of the Clinical Advisory Board at Neuron.

​

Alan Laties M.D. (deceased) was the Harold G. Scheie Professor of Ophthalmology at the University of Pennsylvania.  Alan chaired the SAB at the Foundation Fighting Blindness for three decades, co-founded several biotechs and chaired the Clinical Advisory Board at Neuron.